Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. Our goal is to transform the lives of patients with improved therapeutic options and a patient-centric focus. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with what we believe contain innovative mechanisms of action. As we work to advance our current product pipeline, we plan to explore additional indications identify new product candidates from our existing intellectual property, and acquire rights to additional promising product candidates with significant therapeutic potential. Our executive management team includes globally recognized specialists in neuropsychiatric disease and commercialization of products addressing significant unmet medical needs.
Our strategy is based on four key principles: unwavering commitment to neuropsychiatric patients, their families and communities; scientific rigor; continually leveraging patient and caregiver insights to drive scientific advancement; and an unparalleled commitment to integrity in all of our business dealings. As we work to advance our pipeline of products through clinical development and regulatory review, we may also selectively explore collaborations with leading pharmaceutical companies.
President and Chief Executive Officer
Dr. Remy Luthringer has been involved in the development of more than 150 active molecules for clinical trials in the central nervous system. Dr. Luthringer served as Chief Medical Officer for Index Ventures, with a focus on investments in healthcare infrastructure. He was also the head of the FORENAP Institute for Research in Neurosciences and Neuropsychiatry in France. Dr. Luthringer has extensive experience in clinical psychiatric practice and holds a PhD in neurosciences and clinical pharmacology.
Executive Vice President and
Chief Financial Officer
Prior to being named as Minerva Neurosciences' CFO, Mr. Race served as a consultant for the development of MIN-101 and MIN-117. He has previously served as Chief Executive Officer of Funxional Therapeutics Ltd., the lead program of which (FX125L) was acquired by Boehringer Ingelheim in 2012. He also served as Chief Financial Officer at PanGenetics B.V. He is a Fellow of the Chartered Institute of Management Accountants and earned his MBA from Durham University Business School.
Vice President and Chief Operating Officer
Joe Reilly was most recently Vice President, Head of Commercial Strategy and Operations at Genzyme Corporation. In more than a decade at Genzyme, he also served as Vice President of Global Business Operations, Vice President of Commercial Operations and Vice President of Finance in the Rare Diseases Division. Joe holds a BS and MS in Finance from Boston College.
Vice President and Chief Accounting Officer
Fred Ahlholm was most recently Vice President of Finance and Chief Accounting Officer for Amarin Corporation plc, where he helped direct the growth of the company from a small clinical-stage drug developer into a commercial enterprise of more than 400 employees. Fred is a CPA and earned his BBA at the University of Notre Dame.
Vice President and General Counsel
Mark Levine has extensive experience counseling companies on general corporate matters, complex commercial transactions, mergers and acquisitions, securities law, corporate governance and regulatory compliance. Prior to joining Minerva Neurosciences in 2014, he served in senior legal positions at athenahealth, Inc., Clinical Data, Inc., Wheelabrator Technologies Inc., and Xpedior Incorporated. He holds a bachelor of arts degree from Binghamton University, SUNY, and a juris doctor degree from Washington University School of Law in St. Louis.
Minerva Neurosciences is focused on the field of neuropsychiatry within the central nervous system (CNS) disease pharmaceutical market. Neuropsychiatry is a medical subspecialty devoted to understanding cognitive, emotional, behavioral, and perceptual symptoms resulting from circuit-specific brain dysfunction and includes a range of serious diseases and conditions. Our pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease, each of which affects millions of people around the world. Currently available treatment options for these conditions are known to have significant limitations that can often result in high rates of discontinuation of therapy and unsatisfactory efficacy and safety profiles. Family members also often face significant challenges associated with the burden of these and many other neuropsychiatric diseases. We are pursuing the development of new therapeutic options based on its deep knowledge of the pathology of neuropsychiatric diseases, the pharmacology of its library of compounds and its understanding of desired outcomes for unmet patient needs. We believe our product candidates each have novel mechanisms of action and represent differentiated treatment options with the potential to address significant unmet needs with improved efficacy and safety.
We currently have a portfolio of first-in-class product candidates in the pipeline: MIN-101, MIN-117, MIN-202 and MIN-301.
|Phase 1||Phase 2||Rights|
|1) BA = Bioavailability 2) HV = Healthy Volunteers 3) MAD = Multiple ascending dose|
|MIN-117||Major depressive disorder (MDD)||
1601 Trapelo Road, Suite 284
Waltham, MA 02451
For general inquiries, please contact:
For media inquiries, please contact:
Berry & Company Public Relations
For investor inquiries, please contact:
Stern Investor Relations